Company ProfilePremium

Alcidion Group Limited

Company Profile Analysis

Ticker: CB.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Alcidion Group Limited - Company showcase

Year Founded & Workforce

2000

140 Employees

Alcidion Group Limited logo

Alcidion Group Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Alcidion Group Limited Overview

Alcidion is an Australian-headquartered, UK-weighted health information technology vendor whose flagship Miya Precision platform delivers modular, interoperable clinical software to public hospitals and health systems in Australia, New Zealand and the United Kingdom. Rather than competing head-on with the monolithic "big-bang" electronic patient record (EPR) vendors, Alcidion has historically sold modules — patient flow, observations and assessments, clinical noting, clinical communications and tasking, command-centre visibility, emergency department and virtual care — that sit alongside or on top of incumbent systems. Since 2025 it has graduated into full EPR deployments for mid-sized NHS trusts (North Cumbria in February 2025 and University Hospitals Sussex in May 2026), positioning itself as a modern, cloud-native, modular EPR alternative to Oracle Health and Epic. FY26 revenue was A$51.6M (+27%), annual recurring revenue A$38.3M (+34%) and Underlying EBITDA A$6.8M, with A$20.6M cash and no borrowings.


Company's own description

In its FY26 results release (19 August 2026), Alcidion describes its purpose as transforming healthcare through proactive, smart and intuitive technology that lifts the efficiency and quality of patient care. It characterises its offer as a complementary set of software products and technical services built around Miya Precision, which aggregates information into centralised dashboards, supports interoperability, facilitates clinical and operational communication and task management, and provides clinical decision support at the point of care. The company states that it operates across three established markets — Australia, New Zealand and the United Kingdom — with further geographic expansion planned, and that it now serves over 400 hospitals and 87 healthcare organisations (FY25 AGM materials, October 2025).

Independent characterisation

Alcidion is best understood as a niche enterprise clinical-software vendor in transition from a module seller to a mid-market EPR platform provider. Three features define the business model:

  1. Long-duration public-sector contracts. Customers are overwhelmingly government-funded hospitals (NHS trusts and health boards in the UK; state Local Health Districts/Networks and Hospital & Health Services in Australia; the Australian Defence Force via prime contractor Leidos). Contract terms of 5–10 years, often with extension options, are standard. The North Cumbria EPR is 10 years; UH Sussex is an initial 7 years; South Tees runs to 2033.

  2. Revenue built on recurring product fees plus lumpy implementation and licence revenue. Recurring product revenue (support & maintenance, licence subscriptions, hosting) was A$31.9M in FY26 (≈62% of revenue). The balance is non-recurring: implementation services, technical services, upfront capital licence fees (e.g., ≈A$8.5M recognised in FY26 from UH Sussex) and third-party partner products resold where Alcidion acts as prime contractor.

  3. High gross margins, operating leverage on a fixed cost base. Gross margin has run at 86–88% historically (80.3% in FY26 due to third-party product pass-through). Alcidion does not capitalise internal development costs (H1 FY25 results presentation), so R&D is fully expensed — a conservative policy that depresses reported profit relative to peers that capitalise.

Revenue model mix

Revenue stream (AUD Mn)FY2024FY2025FY2026
Recurring product revenue (S&M, licences, subscriptions, hosting)26.226.031.9
Non-recurring revenue (implementation, services, upfront licences, third-party) — derived residual10.914.819.7
Total revenue37.140.851.6

Source: FY25 results release (FY24 and FY25 recurring "Product – M&S + annual licences" A$26,197k and A$25,968k); FY26 results release (recurring A$31.9M, +23%). Non-recurring is derived as total less recurring. Note: FY23 results reported "recurring revenue" of A$28.1M (≈70% of revenue), which appears to use a broader definition than the FY24–FY26 series; the series are not strictly comparable. The FY24 AGM summary (Quartr) cited recurring revenue at 74% of FY24 revenue, versus 71% derived here — a definitional discrepancy noted.

Value-chain position

Alcidion sits in the application software layer of the hospital IT stack. It integrates with (rather than replaces) patient administration systems (PAS), laboratory and pharmacy systems, and incumbent EMRs from Oracle Health (Cerner) — East Lancashire and Alfred Health are cited integration reference sites (FY23 results) — while in EPR deals it becomes the system of record, supplemented by its own Silverlink PCS PAS and by third-party partners (e.g., Mizaic MediViewer electronic document management at North Cumbria). It also provides technical integration and data services inherited from MKM Health.

Customer types and end-markets

Customer typeExamples (from company disclosures)Market
NHS acute and integrated-care trusts (England)North Cumbria Integrated Care, UH Sussex, South Tees, University Hospital Southampton, Dartford & Gravesham, Bolton, Lancashire Teaching, East Lancashire, Royal Wolverhampton, Moorfields Eye, Liverpool Heart & ChestUK
NHS community trustsHerefordshire & Worcestershire Health and CareUK
Welsh health boardsHywel Dda University Health BoardUK (Wales)
Australian state public health servicesAlfred Health, Western Health, Peninsula Health, Hume Rural Health Alliance (Vic); NALHN (SA); Sydney LHD (NSW); NT Health; Gold Coast Health (Qld)ANZ
Defence healthAustralian Defence Force via Leidos Australia (Health Knowledge Management system)ANZ
Private and public hospitals (via Kyra)≈33 Kyra customers, majority of Queensland Hospital & Health Services plus Vic, WA, Tas public/privateANZ
New Zealand health providersVia MKM Health (NZ) — specific customers not detailed in sources reviewedNZ

Strategy

Stated strategy (themes from FY25/FY26 reporting and the September 2025 roadshow)

Management's stated strategy rests on the following themes (paraphrased from the FY26 results release, FY25 results and AGM/roadshow summaries):

  1. Sustainable growth through long-term, contracted recurring revenue — prioritising multi-year enterprise contracts and ARR growth over one-off revenue.

  2. Organic expansion in established markets — "land and expand": deploying additional Miya modules into existing customers (e.g., Miya Emergency at Hywel Dda and South Tees; Smartpage non-clinical at NCIC; additional beds at Western Health).

  3. Conversion of the NHS installed base to full EPR — from South Tees to North Cumbria to UH Sussex, Alcidion is positioning as the modular EPR alternative for trusts that do not want single-vendor lock-in.

  4. Patient flow leadership — management cites an 18% compound growth forecast for the global patient-flow market to 2034 and positions Alcidion as an industry leader; Kyra was explicitly framed as executing this priority.

  5. Product evolution with AI — Miya AI Service and the SaMD-registered Concept Detection capability.

  6. New territories and adjacencies — Canada and the Middle East; aged care.

  7. Disciplined M&A — with a growing cash position, brokers (Canaccord) see bolt-on acquisitions becoming more tangible; Kyra was the first deal in 4.5 years.

Strategic initiatives (last 24 months)

InitiativeDateDescriptionStatus / targets
Cost restructureQ3 FY24Headcount and cost reduction; A$1.0M one-off costCompleted; ≈A$3.35M half-yearly employee-cost saving (H1 FY25 vs H1 FY24)
North Cumbria EPRFeb 2025Second full EPR; 10 yearsPhase 1 go-live Q4 FY26, on time; TCV now ≈A$50M
Wales market entryFeb 2025Hywel Dda (Miya Flow, Observations, Smartpage)Implemented FY26; expanded with Miya Emergency
South Australia entryOct 2024NALHN (first SA Miya Precision)Implemented FY26
Growth strategy roadshowSep 2025Articulated organic, AI, new-territory and adjacency strategy—
Leidos/ADF expansionNov 2025Third expansion, A$12.3M TCVLeidos ARR ≈A$6.1M; potential lifetime value ≈A$100M
AI medical-device registrationFeb 2026Concept Detection Class I SaMD (Australia and UK)Commercially available as optional module
Queensland entryQ3 FY26Gold Coast Health remote patient monitoring (5 years)Live by Aug 2026
UH Sussex EPRMay 2026Third EPR; first NHS EPR including Virtual CarePhased go-live from spring 2027; full implementation ~2 years
Kyra acquisitionMay–Jun 2026Patient flow consolidation in ANZCompleted 29 Jun 2026; earn-out up to A$1.0M
Reduced reporting burdenSep 2026ASX relief from quarterly 4C reportingNext periodic report: H1 FY27 Appendix 4D by 28 Feb 2027

ESG/sustainability commitments: none quantified in the sources reviewed. Cost programmes with targets: no current programme announced; FY26 salaries rose only 3% with a steady staff base.

Management guidance and medium-term targets

Guidance itemDetailSource
FY27 revenueExpected to exceed FY26 (A$51.6M)FY26 results
FY27 Underlying EBITDAExpected to exceed FY26 (A$6.8M)FY26 results
FY27 contracted revenue (start of year)A$44.9M (+32%), including A$38.3M ARRFY26 results
FY27 gross marginReturn to mid-80% rangeFY26 results
FY27 EBITDA/operating cash flowContracted base provides visibility over a positive result before new salesFY26 results
Long-term contracted revenue≈A$140M of contracted revenue to be recognised out to 2030 (stated at FY25, before UH Sussex and FY26 expansions)FY25 results
Medium-term numerical targets (e.g., margin or revenue targets beyond FY27)——

Products & Services

Because Alcidion reports a single segment, the catalog is organised by product family. Pricing is not publicly disclosed for any product; contracts are typically priced as multi-year total contract value (TCV) combining upfront licence, implementation services and annual support/subscription fees.

Miya Precision platform (flagship)

Product / moduleDescription and capabilitiesTarget customerLaunch / latestNotes
Miya Precision (platform)Cloud-native, modular clinical platform aggregating real-time data from multiple hospital systems into a longitudinal record; interoperability engine; dashboards; clinical decision supportPublic hospitals and health systemsPlatform evolution of original Miya; NT Health upgrade from earlier Miya version disclosed FY22Live in >400 hospitals / 87 organisations (company, 2025)
Miya Precision EPRFull electronic patient record configuration combining Miya modules with Silverlink PCS PAS and partner productsMid-to-large NHS trustsFirst EPR: South Tees (extended to 2033); NCIC (Feb 2025); UH Sussex (May 2026)Three UK EPR contracts; NCIC Phase 1 go-live Q4 FY26
Miya FlowEnterprise patient flow and bed management — real-time view of patient journey, capacity and dischargeAcute hospitals, community trustsDeployed Alfred Health (3 campuses), Bolton (replacing ExtraMed), Herefordshire & Worcestershire, Hywel DdaCompany describes itself as an industry leader in patient flow
Miya AccessAccess/capacity visibility module (deployed with Flow and Command)Acute hospitalsAlfred Health go-live (FY23)—
Miya CommandCommand-centre view of hospital operationsLarge health servicesAlfred Health (FY23); Western Health expansion (Q4 FY26)—
Miya NotingStructured and free-text clinical documentationEPR and module customersSouth Tees rollout (FY23)Host module for Concept Detection
Miya Concept Detection (AI)AI-assisted feature within Miya Noting that reads free-text clinician notes, identifies medical concepts and suggests standard codes for clinician reviewExisting Miya customers; new EPR customersRegistered Class I SaMD in Australia (ARTG) and UK (MHRA), announced 19 Feb 2026Sold as an optional module
Miya AI ServiceProprietary secure architecture for deploying AI capabilities inside Miya PrecisionMiya customersAnnounced Feb 2026Foundation for future AI features
Miya Observations & Assessments (formerly Patientrack)Digital vital-signs capture, early-warning scores (e.g., NEWS2), nursing assessmentsAcute hospitalsAcquired Jul 2018; already live at UH Sussex prior to EPR awardRenewals reported Q3 FY26
Miya Emergency (Miya ED)ED-specific module for fast-paced emergency workflowsAcute trustsExpansions at Hywel Dda and South Tees (Q3 FY26)Optional module in UH Sussex contract
Miya Virtual Care / Remote Patient MonitoringHospital-in-the-home and remote monitoringHealth services expanding virtual careSydney LHD (FY22); Gold Coast Health 5-yr contract (Q3 FY26, live by Aug 2026); UH Sussex is the first NHS trust to include Virtual Care in an EPR—
SmartpageClinical communications and task management (replacing pagers); expanded to non-clinical communicationsAcute hospitalsLancashire Teaching (company reports at least 2 hours saved per 12-hour shift); NCIC clinical then non-clinical (FY26)—

Patient administration

ProductDescriptionTarget customerLaunch / latestNotes
Silverlink PCS (PAS)Patient Administration System — registration, scheduling, admissions/discharges/transfers, waiting lists; integrates with other clinical systemsNHS trustsAcquired Dec 2021; renewals at Moorfields Eye, Liverpool Heart & Chest, Royal WolverhamptonOne of the last independent specialist PAS vendors in the NHS market

Kyra flow products (acquired 29 June 2026)

ProductDescriptionTarget customerNotes
Kyra Patient Flow ManagerReal-time oversight of inpatient journey from admission to discharge; bed managementQueensland HHSs (majority), Vic/WA/Tas public and private hospitals≈33 customers; top-10 customers average ≈10-year tenure
Kyra Queue ManagerOutpatient check-in, queuing, wayfinding and appointment flowOutpatient departments—
Kyra IQData consolidation, referral management, triage and operational reportingHealth service operations—

FY26 (pro forma) revenue ≈A$3.7M with >90% recurring; ARR ≈A$3.6M at 30 June 2026 (acquisition announcement 18 May 2026; FY26 results).

Legacy and services

OfferingDescriptionNotes
ExtraMedUK patient-flow software acquired Apr 2021Being migrated to Miya Flow (e.g., Bolton FY23); contributed the Herefordshire & Worcestershire win
Technical services (MKM Health heritage)Systems integration, health-data analytics, real-time data replicationSupports implementation revenue
HostingHosted/cloud delivery of Miya PrecisionIncluded in recurring revenue definition
Third-party partner products (prime contracting)e.g., Mizaic MediViewer EDMS at NCIC; third-party licences in UH Sussex scopeLower gross margin; drove FY26 gross margin to 80.3%

Financial Narrative

Sources: S&P Global Market Intelligence (via StockAnalysis.com) for statutory line items FY2022–FY2026; company results releases for underlying EBITDA, ARR and commentary. All AUD millions unless otherwise labelled.

Income statement

Notes: Company-reported EBITDA: FY22 −A$1.6M and FY23 −A$1.5M (FY23 release); FY24 −A$4.545M and FY25 A$4.843M (FY25 release); FY26 A$6.2M (FY26 release summary). The S&P series differs because it treats FX gains/losses, share-based payments and certain one-offs differently. EPS is derived from NPAT ÷ weighted shares; the FY26 release reports NPAT A$2.3M, +38%. Tax line sign convention: S&P shows negative "income tax expense" (i.e., a benefit) in FY23–FY26.

Underlying EBITDA (company measure: EBITDA excluding restructure costs and share-based payments)

Source: FY25 and FY26 results releases. Margin derived.

Margins

Revenue CAGR: FY2022→FY2026 (4 years) ≈10.7% p.a.; FY2021 (A$25.88M) → FY2026 (5 years) ≈14.8% p.a. (derived from S&P revenue series).

Commentary — income statement. The five-year record divides into three phases. Phase 1 (FY22–FY23): acquisitive growth with cost build. Revenue rose 33% in FY22 and 18% in FY23, boosted by the Silverlink and ExtraMed acquisitions, but SG&A grew faster (salaries +27% in FY23 per the FY23 release, reflecting Silverlink staff, H2 FY22 hires and ~10 extra roles in cyber security and product support) as management staffed for a UK EPR procurement wave that then slipped. Phase 2 (FY24): the trough. Revenue fell 8% to A$37.1M as Alcidion's portion of the Leidos/ADF implementation neared completion and an Australian third-party contract was restructured from prime to subcontract; NPAT was −A$8.4M. Management executed a cost restructure in Q3 FY24 (A$1.0M one-off cost), and the FY25 H1 results show a A$3.35M half-on-half reduction in employee benefits expense. Phase 3 (FY25–FY26): operating leverage. With the cost base reset and NHS EPR wins (North Cumbria, then UH Sussex) converting, revenue grew 10% then 27%, SG&A rose only 6% in FY26, and EBIT turned positive (A$2.55M) for the first time in the period. The FY26 gross margin dip (80.3% vs 88.2%) is attributable to third-party product revenue under prime-contract arrangements; management guides to a return to the mid-80% range in FY27.

Balance sheet

Note: Alcidion has no bank borrowings; the only "debt" is AASB 16 lease liabilities. The company consistently describes itself as having "no debt."

Commentary — balance sheet. Goodwill and intangibles (A$91.1M) constitute ~75% of total assets, a legacy of the MKM/Patientrack (2018), ExtraMed (2021) and Silverlink (2021) acquisitions; tangible book value is approximately nil (−A$0.18M at FY26 per S&P). No goodwill impairment has been recorded in the period, which the FY25–FY26 earnings recovery and the UK EPR wins support. Intangibles amortise at ≈A$1.4–1.5M per year (S&P "other amortization"). Cash troughed at A$7.7M at 31 December 2024 (H1 FY25 release) — the low point of the cycle — before recovering to A$20.6M at June 2026 despite the A$1.5M net Kyra completion payment. Unearned revenue of ≈A$14–15M (invoiced in advance) is a structural feature that funds working capital: Alcidion bills annual support in advance, and H2 (particularly Q4) is the seasonal peak for cash collection.

Cash flow

Notes: FY23 acquisition outflow (A$2.69M) is understood to relate to deferred/contingent Silverlink consideration (FY22 presentation references a second Silverlink tranche); FY26 outflow is the A$1.5M net Kyra completion payment (A$3.0M upfront less completion adjustments). Company-reported FY26 operating cash flow: A$6.8M, +19%, representing ~100% conversion of Underlying EBITDA.

Commentary — cash flow. Alcidion is a capital-light business (capex <1% of revenue) because development costs are expensed, so operating cash flow ≈ free cash flow. The FY24 outflow (−A$7.1M) reflected both losses and an adverse H1 seasonal pattern; H2 FY24 operating cash flow was already positive (+A$4.3M). FY26 cash generation was flattered by a large Q4 receipt (A$24.6M quarterly receipts including a A$10.6M UH Sussex upfront licence payment, Q4 FY26 4C), partly offset by A$4.1M of product costs for third-party licences in that quarter. Full-year FY26 cash receipts were A$56.1M.

Ratios

Other ratios (FY26 / TTM, S&P Global unless stated): ROIC 1.76%; ROCE 2.62%; interest coverage ≈44.8x (EBIT ÷ lease interest); net debt/EBITDA not meaningful (net cash of A$19.8M ≈ 2.9x Underlying EBITDA); cash conversion cycle not meaningful for a software business with no inventory and customer prepayments (effectively negative working-capital cycle given unearned revenue exceeds receivables).

Commentary — ratios. Returns remain thin (ROE ≈2.5%) because ≈A$91M of acquired goodwill and intangibles sits in the equity base while earnings have only just turned positive. The improving trajectory is the point: if Underlying EBITDA of A$6.8M grows as guided and intangible amortisation steadily declines, ROE could reach high single digits without any balance-sheet change. Liquidity has strengthened (current ratio 1.22x), and the negative working-capital profile is a structural strength.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityJurisdictionOrigin

Alcidion Group Limited

Australia

Listed parent

Alcidion Corporation Pty Ltd

Australia

Founding operating company

MKM Health Pty Ltd

Australia

Acquired 3 Jul 2018

MKM Health (NZ) Ltd

New Zealand

Acquired 3 Jul 2018

Patientrack Holdings Ltd; Patientrack (UK) Ltd; Patientrack Pty Ltd

UK / Australia

Acquired 3 Jul 2018

MKM Consulting (UK) Ltd

UK

Dormant; acquired with Patientrack

ExtraMed (UK entity)

UK

—

Silverlink PCS Software Ltd

UK

Acquired Dec 2021

Kyra flow business and assets

Australia

Asset acquisition completed 29 Jun 2026 (no entity acquired)

Revenue by Segment and Revenue by Segment (%)

MetricFY2024FY2025FY2026

Recurring product revenue (AUD Mn)

26.226.031.9

Non-recurring revenue, derived (AUD Mn)

10.914.819.7

Total revenue (AUD Mn)

37.140.851.6

Recurring share of revenue (%)

70.763.761.8

Recurring YoY growth (%)

—-0.922.7

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

ARR at 30 June (AUD Mn)

21.828.538.3

ARR YoY growth (%)

—3134

Revenue by Segment

MetricFY2024FY2025FY2026FY2027

Contracted (sold + renewal) revenue for the year, at start of year (AUD Mn)

33.728.034.044.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (AUD Mn)

34.3640.4037.0640.7951.64

Revenue growth (%)

32.717.6-8.310.126.6

Cost of revenue (AUD Mn)

4.865.635.144.8010.18

Gross profit (AUD Mn)

29.4934.7731.9235.9941.46

SG&A (AUD Mn)

25.6232.1531.2628.1829.75

Operating income / EBIT (AUD Mn)

-1.73-4.73-7.68-0.562.55

EBITDA, S&P definition (AUD Mn)

-0.65-3.73-5.771.945.34

EBITDA, company-reported (AUD Mn)

-1.6-1.5-4.54.86.2

Restructuring / M&A charges (AUD Mn)

2.140.001.030.120.41

Pre-tax income (AUD Mn)

-3.91-4.74-8.700.321.32

Income tax benefit (+) / expense (-) (AUD Mn)

-0.501.120.281.330.97

Net income / NPAT (AUD Mn)

-4.41-3.62-8.421.652.29

Weighted shares, basic (M)

1,1641,2681,3161,3431,343

EPS basic, derived (AUD cents)

-0.38-0.29-0.640.120.17

EPS diluted, derived (AUD cents)

-0.38-0.29-0.640.120.17

Dividends per share (AUD cents)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%) (FY2024–FY2026)

MetricFY2024FY2025FY2026

Underlying EBITDA (AUD Mn)

-3.45.16.8

Underlying EBITDA margin (%)

-9.112.513.2

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

85.886.186.188.280.3

Operating (EBIT) margin (%)

-5.0-11.7-20.7-1.44.9

EBITDA margin, S&P (%)

-1.9-9.2-15.64.810.3

Net margin (%)

-12.8-9.0-22.74.04.4

Balance Sheet and Share Count (M)

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (AUD Mn)

128.35120.68114.46115.63121.88

Cash and equivalents (AUD Mn)

17.3414.6411.8017.7020.64

Accounts receivable (AUD Mn)

7.253.303.553.685.24

Goodwill (AUD Mn)

67.7667.7667.7667.7668.68

Other intangibles (AUD Mn)

31.0629.0726.1922.5922.37

Goodwill + intangibles (AUD Mn)

98.8296.8393.9590.3591.05

Short-term debt — current lease liabilities (AUD Mn)

0.620.690.700.710.53

Long-term debt — non-current lease liabilities (AUD Mn)

1.871.461.000.690.28

Total debt incl. leases (AUD Mn)

2.482.161.701.410.81

Net cash (AUD Mn)

14.8612.4910.1016.2919.83

Current unearned revenue (AUD Mn)

12.9111.6112.8315.0414.41

Total liabilities (AUD Mn)

34.4030.5227.5227.8331.01

Shareholders' equity (AUD Mn)

93.9690.1786.9487.8090.87

Working capital (AUD Mn)

1.87-0.30-0.672.835.28

Shares outstanding, period end (M)

1,2681,2681,3421,3431,344

Cash Flow and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

1.000.17-7.135.766.85

Capital expenditure (AUD Mn)

-0.31-0.45-0.05-0.13-0.23

Free cash flow (AUD Mn)

0.69-0.29-7.185.646.62

Free cash flow margin (%)

2.0-0.7-19.413.812.8

Cash acquisitions (AUD Mn)

-59.43-2.690.000.00-1.48

Equity issued (AUD Mn)

51.940.005.400.000.00

Lease principal repaid (AUD Mn)

-0.61-0.62-0.66-0.76-0.80

Dividends paid (AUD Mn)

00000

Share buybacks (AUD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE on closing equity, derived (%)

-4.7-4.0-9.71.92.5

ROA on closing assets, derived (%)

-3.4-3.0-7.41.41.9

Current ratio (x)

1.080.990.971.141.22

Debt (leases) to equity (x)

0.0260.0240.0200.0160.009

Asset turnover, derived (x)

0.270.330.320.350.42

Days sales outstanding, derived (days)

7730353337

Unearned revenue / revenue (%)

37.628.734.636.927.9

Revenue by Region (%) and Revenue by Region

MetricFY2025FY2026

UK share of revenue (%)

6363

ANZ share of revenue (%)

3737

UK revenue, derived (AUD Mn)

25.732.5

ANZ revenue, derived (AUD Mn)

15.119.1

UK revenue growth, derived (%)

—26.5

ANZ revenue growth, derived (%)

—26.5

Valuation Snapshot

MetricValueSource

Share price

A$0.105

S&P Global via StockAnalysis

Market capitalisation

A$141.1M

S&P Global

Enterprise value

A$121.3M

S&P Global

52-week price change

+12.9%

S&P Global

50-day / 200-day moving average

A$0.10 / A$0.10

S&P Global

Beta (5-year)

1.03

S&P Global

Average volume (20 days)

≈538,000 shares

S&P Global

P/E (trailing)

58.8x

S&P Global

P/E (forward)

48.1x

S&P Global

EV/Sales (FY26)

2.22x

S&P Global

EV/EBITDA (S&P EBITDA)

18.9x

S&P Global

EV/Underlying EBITDA (A$6.8M), derived

17.8x

Derived

EV/ARR (A$38.3M), derived

3.2x

Derived

P/B

1.48x

S&P Global

FCF yield

4.9%

S&P Global

Capital Markets Data (AUD)

MetricFY2021FY2022FY2023FY2024FY2025

52-week low before annual report date (AUD)

0.1050.0920.0440.0490.088

52-week high before annual report date (AUD)

0.3970.1750.1250.1100.140

Analyst Ratings & Targets

BrokerDateRatingTarget (AUD)Notes

Bell Potter (Thomas Wakim)

15 Jan 2026

Buy

0.17 (from 0.15)

FY26/FY27/FY28 revenue forecasts A$52.6M / A$56.4M / A$61.0M

Canaccord Genuity

2026——

Highlighted execution on UH Sussex and potential acquisitions

Consensus (S&P Global, 4 analysts)

Oct 2026

Buy

0.15 (+43% vs A$0.105)

3-year revenue growth forecast ≈11% p.a.; 3-year EPS growth ≈34% p.a.

Capital Markets

ItemStatus

Dividend history

No dividends paid FY22–FY26; S&P lists no current dividend. (A German aggregator lists a 2022 distribution; which is not corroborated by S&P cash-flow data showing nil dividends paid)

Dividend policy

Not publicly disclosed; cash retained for growth and M&A

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

Lease liabilities only: A$0.53M current, A$0.28M non-current (30 June 2026)

Analyst Conclusions

Management guidance (FY27)

Revenue and Underlying EBITDA are expected to exceed FY26 levels (A$51.6M and A$6.8M respectively); the year begins with record contracted revenue of A$44.9M, including A$38.3M ARR; gross margin is expected to recover to the mid-80% range; and management states the contracted base alone gives visibility over positive EBITDA and operating cash flow before new FY27 sales (FY26 results, 19 August 2026).

Consensus expectations

Bell Potter (January 2026) forecast FY27 revenue of A$56.4M and FY28 of A$61.0M; S&P Global consensus implies ≈11% annual revenue growth over three years and ≈34% EPS growth. The mechanical challenge for FY27 is replacing ≈A$8.5M of one-off UH Sussex licence revenue recognised in FY26 with recurring fees (UH Sussex recurring revenue, a full year of Kyra at ≈A$3.6–3.7M, and Leidos/NCIC expansions).

Bull case

  1. ARR compounding plus Kyra: ARR has grown 31% and 34% in consecutive years; Kyra adds ≈A$3.6M of >90% recurring revenue bought at ≈2.7x EBITDA, and UH Sussex recurring fees start in FY27 — supporting ARR well above A$40M within FY27.

  2. EPR credibility flywheel: three NHS EPR wins in roughly three years, with NCIC delivered on time, make Alcidion a credible shortlist vendor for every mid-sized trust EPR tender.

  3. Valuation versus cash generation: EV of ≈A$121M equals ≈3.2x ARR and ≈18x Underlying EBITDA for a business growing ARR >30% with net cash and ≈100% EBITDA-to-cash conversion; operating leverage (salaries +3% vs revenue +27%) should expand margins further.

Bear case

  1. FY27 revenue air-pocket: FY26 included ≈A$8.5M of non-recurring UH Sussex licence revenue plus implementation and third-party revenue; if new upfront deals do not land, headline growth could slow sharply even as ARR rises.

  2. Execution concentration: with ≈140 staff, simultaneous delivery of NCIC later phases, UH Sussex (go-live from spring 2027) and Leidos expansions creates single-point-of-failure risk; a troubled go-live would damage the reference pipeline.

  3. Low returns and dilution history: ROE ≈2.5%, goodwill-heavy balance sheet, and equity raises in FY22 and FY24; further M&A could again require equity if larger targets emerge.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timing
2026 AGM — trading commentary and any FY27 guidance refinementOct–Nov 2026
New NHS EPR or major module contract winsOngoing
Kyra integration and earn-out outcome (12-month recurring-revenue test)By ≈Jun 2027
Cross-sell of Miya Precision into Kyra/Queensland customersFY27
UH Sussex readiness milestones ahead of phased go-liveThrough spring 2027
NCIC subsequent phase go-livesFY27
H1 FY27 results (Appendix 4D) — first test of gross-margin recovery and ARRBy 28 Feb 2027
Further bolt-on M&A using A$20.6M cashOpportunistic
Commercial uptake of Concept Detection / Miya AI ServiceFY27
Progress in new territories (Canada, Middle East) or aged careLonger-dated

Concluding analyst verdict

Alcidion has completed the most important transition in its 25-year history: from a cash-hungry, acquisitive module vendor that lost A$8.4M in FY24 to a self-funding, profitable platform company with A$38.3M of ARR, A$6.8M of Underlying EBITDA and A$20.6M of net cash two years later. The evidence for the turnaround is not merely financial. Three competitively tendered NHS EPR contracts, an on-time Phase 1 go-live at North Cumbria, four expansions at the Australian Defence Force and a disciplined, low-multiple consolidation of Telstra Health's Kyra products together suggest a business whose modular, interoperable proposition has found product-market fit with mid-sized public health systems.

The investment debate is now about durability and scale rather than survival. The FY26 result was flattered by a large upfront licence and third-party pass-through revenue, so FY27 headline growth will be modest unless new contracts land; the cleaner metric is ARR, where management's starting position (A$44.9M contracted, +32%) is strong. Execution risk is the principal concern: a 140-person company is simultaneously delivering several of the most complex software implementations in healthcare, and its reputation — and therefore its pipeline — depends on each one going live well. Concentration in a handful of customers and the goodwill-heavy balance sheet keep statutory returns low for now.

At roughly 3x ARR and under 18x Underlying EBITDA, with net cash and near-total cash conversion, the market appears to price Alcidion as a steady micro-cap rather than a business compounding recurring revenue above 30%. If FY27 delivers ARR above A$45M, gross margin back in the mid-80s and at least one further EPR or major module win, the case for a re-rating towards broker targets (A$0.15–0.17) is credible. The balance of evidence supports a constructive view, conditioned on monitoring UH Sussex readiness and Kyra integration closely, and recognising that reduced reporting frequency from FY27 will make interim monitoring harder.


APPENDIX — SOURCE REGISTER

  • ASX: FY26 Full Year Results release (Alcidion) — announcements.asx.com.au/asxpdf/20260819/pdf/072x6kdhwcr1d4.pdf — 19 Aug 2026 — FY26 financials, ARR, contracts, Kyra, outlook, headcount

  • ASX: Q4 FY26 Quarterly Activities Report — announcements.asx.com.au/asxpdf/20260723/pdf/071z7fnh1b6f8t.pdf — 23 Jul 2026 — Cash flow, Q4 TCV, Kyra payment

  • ASX: FY26 trading update — announcements.asx.com.au/asxpdf/20260629/pdf/0713dqlcc8xq7s.pdf — 29 Jun 2026 — Kyra completion

  • ASX: UH Sussex contract — announcements.asx.com.au/asxpdf/20260525/pdf/06zxjp8140vbrr.pdf — 25 May 2026 — UH Sussex terms

  • ASX: Kyra acquisition — announcements.asx.com.au/asxpdf/20260518/pdf/06zp94b3v05k8y.pdf — 18 May 2026 — Kyra deal

  • ASX: Q3 FY26 4C — announcements.asx.com.au/asxpdf/20260429/pdf/06yz2ypw46c3pn.pdf — 29 Apr 2026 — Q3 FY26

  • ASX: H1 FY26 Results — announcements.asx.com.au/asxpdf/20260226/pdf/06wrxgdf6gvjpx.pdf — 26 Feb 2026 — H1 FY26

  • ASX: SaMD registration — announcements.asx.com.au/asxpdf/20260219/pdf/06whcyy4qvwl28.pdf — 19 Feb 2026 — AI regulatory

  • ASX: Form 604 — announcements.asx.com.au/asxpdf/20260119/pdf/06vdbkdcf4gtx0.pdf — 19 Jan 2026 — Substantial holder

  • ASX: ASX 4C relief — investorpa.com/announcement-pdf/20260903/338309.pdf — 3 Sep 2026 — Reporting relief, address

  • ASX: FY25 Full Year Results — announcements.asx.com.au/asxpdf/20250828/pdf/06ng58pgg8mfy9.pdf — 28 Aug 2025 — FY24–FY25 data

  • ASX: H1 FY25 Results — announcements.asx.com.au/asxpdf/20250227/pdf/06g0kr3jv8f03q.pdf — 27 Feb 2025 — H1 FY25

  • ASX: Q3 FY25 4C — announcements.asx.com.au/asxpdf/20250422/pdf/06hxltgt2skh8t.pdf — 22 Apr 2025 — NCIC/Hywel Dda

  • ASX: FY24 Full Year Results — announcements.asx.com.au/asxpdf/20240829/pdf/0676qqlkdb5xlt.pdf — 29 Aug 2024 — FY24

  • ASX: FY23 Full Year Results — announcements.asx.com.au/asxpdf/20230824/pdf/05t03g1bnr0csy.pdf — 24 Aug 2023 — FY23

  • ASX: FY22 results presentation — announcements.asx.com.au/asxpdf/20220830/pdf/45dgpncwd11qp0.pdf — 30 Aug 2022 — Silverlink, board changes

  • ASX: FY19 Annual Report — announcements.asx.com.au/asxpdf/20190829/pdf/447zwdj35vf9mh.pdf — 29 Aug 2019 — MKM/Patientrack

  • S&P Global via StockAnalysis.com (income statement, balance sheet, cash flow, statistics) — Updated to 6 Oct 2026 — Five-year financials, market data

  • Bell Potter research — bellpotter.com.au/wp-content/uploads/2026/01/ALC-20260115.pdf — 15 Jan 2026 — Rating, forecasts

  • FNArena ALC page — 2026 — Broker commentary (Bell Potter, Canaccord)

  • Quartr event summaries (FY26, Q4 FY26, AGM 2025) — 2026 — AGM, board changes, geographic split

  • Digital Health (digitalhealth.net) — Silverlink 2021; UH Sussex Jan and Jun 2026 — 2021–2026 — Deal values, UH Sussex

  • TechMarketView — 26 Jun 2026 — UH Sussex context, Hywel Dda

  • SmallCaps; MT Newswires; Nelson Advisors; HINZ — May–Jul 2026 — Kyra terms and context

  • Lawyers Weekly; Oaklins — 2021 — Silverlink value, advisers

  • MarketScreener / MarketIndex / TipRanks / Simply Wall St — 2025–2026 — Director profiles, shareholdings

  • StockLight — 2016–2026 — Announcement history, annual-report trading ranges

  • CB Insights — — — Listing date, PIPE, deal dates

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / background

Kate Quirke

Group Managing Director & CEO

CEO since 3 Jul 2018; later appointed MD

CEO of MKM Health (acquired by Alcidion, 2018)

Matthew Gepp

Chief Financial Officer

In role since at least Aug 2023 (hosted FY23 results webcast)

—

Dr Malcolm Pradhan

Co-founder (historically Chief Medical Officer / executive director)

Since 2000

Clinician and health informatician

Lynette Ousby

UK Managing Director (as at Dec 2021)

——

Board of Directors

NameRoleIndependenceAppointedBackground

Rebecca Wilson

Non-Executive Chair

Independent (presumed)

NED Jul 2017; Chair 30 Aug 2019

CEO of Buchan Consulting (since 2014); NED Hansen Technologies (2024), Vitura Health (2024); Chair Clever Culture Systems (2023); ~25-year executive career in communications, investor relations, capital management; Deakin University

Kate Quirke

Group Managing Director & CEO

Executive

2018

See above

Prof. Andrew Way AM

Non-Executive Director

Independent

2025 (elected at Oct 2025 AGM)

15+ years as CEO of Alfred Health; Chair of HealthShare Victoria; Adjunct Clinical Professor, Monash University; UK and Australian health-system leadership

Daniel Sharp

Non-Executive Director

—

1 Sep 2021

—

Victoria Weekes

Former NED and Audit & Risk Chair

—

Sep 2021 – retired Jun 2025

Ex-Citigroup MD, Westpac EGM; NED Bendigo & Adelaide Bank; former Chair Sydney LHD

Board & Management Changes

DateChangeContext

3 Jul 2018

Kate Quirke becomes CEO; Ray Blight steps down

MKM Health/Patientrack acquisition

1 Sep 2021

Victoria Weekes and Daniel Sharp appointed NEDs

Board strengthening post-Silverlink

17 Nov 2021

Nick Dignam resigns

—

Jun 2025

Victoria Weekes retires

Board renewal

2025

Prof. Andrew Way AM appointed (elected Oct 2025)

Adds health-system CEO experience

Major Shareholders

HolderShares (M)% of issued capitalAs atSource

AustralianSuper Pty Ltd

153.111.4

2025 (Simply Wall St data)

Aggregator; Jan 2026 substantial-holder changes may have altered this (see below)

Dr Malcolm Pradhan (co-founder)

134.610.02,025

Simply Wall St

Ray Blight (co-founder)

68.75.11

25 Jul 2025

MarketScreener

Kate Quirke (MD & CEO)

≈43.6

≈3.2

Mar 2025 (after selling 5.0M shares)

ASX/TipRanks

Rebecca Wilson (Chair)

1.90.14

30 Jun 2025

MarketScreener

Victoria Weekes (former NED)

0.40.03

30 May 2025

MarketScreener

Top 20 shareholders combined

—43.75

Nov 2025

Simply Wall St

Competitive Landscape

Key Competitors

CompetitorOwnershipCompetes inRelative positioning vs Alcidion

Oracle Health (formerly Cerner)

Oracle Corp. (NYSE: ORCL)

Full EPR (UK, Australia)

Incumbent at many NHS trusts and Australian states; scale far larger; Alcidion often integrates with Cerner and markets itself as a modular alternative

Epic Systems

Private (US)

Full EPR (large NHS trusts; select Australian health services)

Dominant in large academic centres; premium price and big-bang model — Alcidion targets trusts seeking lower cost/modularity

Dedalus

Private (Ardian-backed)

EPR, PAS (UK, ANZ)

—

System C (Careflow)

Private (UK)

EPR, PAS, patient flow, clinical communications (UK)

Direct UK modular competitor

Nervecentre

Private (UK)

Observations, patient flow, clinical communications, EPR (UK)

Closest UK functional overlap with Patientrack/Smartpage/Miya Flow

Altera Digital Health (Sunrise, Paragon)

Private (Harris/Constellation group)

EPR, PAS (UK, Australia)

Legacy PAS/EPR incumbent at NHS trusts

MEDITECH

Private (US)

EPR (UK trusts, some Australian services)

Mid-market EPR competitor

InterSystems (TrakCare)

Private (US)

EPR/PAS (Australia, UK)

State-wide PAS/EPR deployments in Australia

TPP (SystmOne)

Private (UK)

Community/primary/integrated EPR (UK)

Community-care EPR competitor

Telstra Health (pre-2026 for patient flow)

Telstra Group (ASX: TLS)

Patient flow (Kyra) — exited via sale to Alcidion

Competitor removed from ANZ patient-flow market by the Kyra deal

Better (Better Meds / open platform)

Private

ePMA and clinical data platform (UK)

Adjacent; potential partner or competitor

Peer Comparison FY2026

CompanyLatest revenueGrowthMarginsNotes

Alcidion (FY26)

A$51.6M

+27%

Gross 80.3%; Underlying EBITDA 13.2%; net 4.4%

Source: FY26 results

Oracle Health

Not separately disclosed by Oracle

——

Cerner's last standalone revenue (CY2021) was ≈US$5.8B (pre-acquisition filings)

Epic Systems

Private; press reports indicate annual revenue in the US$5–6B range

———

Dedalus

Private; not publicly disclosed in sources reviewed

———

System C, Nervecentre, Altera

Private

———

Company Snapshot

$33.3M

Revenue

140

Employees

2000

Founded

Victoria, Australia

Headquarters

SWOT Analysis

Strengths

  • Accelerating, high-quality recurring base: ARR rose 31% to A$28.5M (FY25) and 34% to A$38.3M (FY26) (FY25 and FY26 results).
  • Contract visibility: FY27 contracted revenue of A$44.9M (+32%) represents ~87% of FY26 revenue before new sales (FY26 results).
  • Proven EPR credentials: three UK EPR contracts (South Tees, NCIC, UH Sussex), with NCIC Phase 1 delivered on time in Q4 FY26 (FY26 results).
  • Balance sheet: A$20.6M cash, no borrowings, operating cash flow A$6.8M (100% conversion of Underlying EBITDA) (FY26 results).
  • Operating leverage demonstrated: revenue +27% with salaries +3% and Underlying EBITDA +34% in FY26 (FY26 results).
  • Regulated AI: Concept Detection registered as Class I SaMD in both Australia and the UK (ASX, 19 Feb 2026).
  • Sticky, long-tenured customers: Kyra's top-10 customers average ~10-year relationships; South Tees extended to 2033 (Kyra announcement; Digital Health).

Weaknesses

  • Low statutory returns: ROE ≈2.5% and ROIC ≈1.8% (S&P, FY26) given ≈A$91M of acquired goodwill/intangibles.
  • Gross margin dilution from pass-through products: 80.3% in FY26 vs 88.2% in FY25 (FY26 results).
  • Lumpy revenue: FY24 revenue fell 8% when the Leidos implementation rolled off (FY24 results); FY26 included ≈A$8.5M one-off UH Sussex licence revenue.
  • Concentration: NCIC TCV ≈A$50M over 10 years and UH Sussex ≈A$35M versus A$51.6M annual revenue (FY26 results).
  • Thin disclosure: no segment profit, no R&D line, and from September 2026 no quarterly cash-flow reports (ASX relief, 3 Sep 2026).
  • History of capital raising: ≈A$51.9M (FY22) and ≈A$5.4M (FY24) issued (S&P cash flow) — shares outstanding up from ≈1,164M (FY22 weighted) to ≈1,344M.
  • Small team: ≈140 employees running multiple concurrent large implementations (FY26 results).

Opportunities

  • UH Sussex recurring fees from FY27 — recurring revenue from this contract commences in FY27 (FY26 results).
  • Kyra cross-sell — introducing Miya Precision to ≈33 Kyra customers, mostly Queensland HHSs (FY26 results).
  • Module expansion — Miya Emergency, Virtual Care, Smartpage non-clinical, Concept Detection sold into >400 hospitals (company materials).
  • Further NHS EPR procurements — mid-sized trusts lacking modern EPRs; Alcidion now has three references.
  • New geographies — Canada and Middle East flagged in the September 2025 strategy update.
  • Bolt-on M&A — Kyra bought at ≈2.7x EBITDA demonstrates accretive consolidation potential with A$20.6M cash.

Threats

  • Big-vendor competition — Oracle Health and Epic dominate large EPR procurements.
  • Implementation risk — a delayed or troubled UH Sussex go-live (phased from spring 2027) would damage reputation.
  • Public-funding cycles — prior procurement delays directly cut FY23 EBITDA (FY23 results).
  • FX — ≈63% of revenue in the UK; AUD/GBP moves create translation volatility (FX loss A$0.93M in FY26 per S&P).
  • Cyber-attack — health IT vendors are prime targets; Alcidion added cyber-security roles in FY23 (FY23 results).
  • Customer renewal risk — long contracts eventually re-tender (e.g., Western Health was extended in FY26 rather than lost).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
22 Apr 2025Q3 FY25 4C: NCIC A$37.5M 10-year EPR and Hywel Dda A$5.5M 5-year contracts reported; operating cash flow improved A$3.9M vs Q3 FY24Confirms UK EPR momentum
Jun 2025Victoria Weekes retires; Prof. Andrew Way AM joins boardBoard renewal with health-system expertise
Jul 2025Q4 FY25 4C: record new sales and positive operating cash flow; shares up ≈12.5% on the day (aggregator report)Turnaround evidence
28 Aug 2025FY25 results: revenue A$40.8M (+10%), Underlying EBITDA A$5.1M (+A$8.5M), ARR A$28.5M (+31%), cash A$17.7M, A$73.8M new TCVFirst year of solid profitability
Mid-Sep 2025Growth strategy roadshow: organic expansion, AI, Canada/Middle East, aged careArticulated medium-term plan
16 Oct 2025AGM: remuneration report adopted; Andrew Way electedGovernance stable
28 Oct 2025Q1 FY26 4C: A$8.2M TCV incl. A$6.8M NCIC expansion; FY26 contracted revenue A$36.3M; cash A$16.4MStrong start to FY26
31 Oct 2025Notification of cessation of securitiesRoutine (lapsed options/rights)
17 Nov 2025Leidos Australia/ADF expansion, A$12.3M TCV (third expansion)Deepens largest ANZ customer
26 Nov 2025Unquoted securities issuedRoutine equity incentives
9 Jan 2026UH Sussex selects Alcidion as preferred EPR supplierThird EPR; largest trust yet
13–15 Jan 2026Substantial holder sells ≈26.4M shares at A$0.12–0.14 (Form 604, 19 Jan)Overhang reduction / institutional rotation
15 Jan 2026Q2 FY26 4C: FY26 contracted revenue already above FY25; A$8.8M cash received in first fortnight of JanuaryGuidance raised to revenue >A$50M, EBITDA >A$5M (per broker commentary)
15 Jan 2026Bell Potter retains Buy, lifts target to A$0.17; raises FY26–28 revenue forecasts by ≈A$6M p.a.Sell-side upgrade
23 Jan 2026Further change in substantial holdingRegister rotation continues
19 Feb 2026Concept Detection Class I SaMD registration in Australia and UKFirst regulated AI module
26 Feb 2026H1 FY26 results: revenue A$25.5M (+44%), Underlying EBITDA A$4.2M (+675%), ARR A$31.1M; guidance reconfirmedRecord half
Q3 FY26Gold Coast Health 5-year RPM contract (first Queensland Miya site); Hywel Dda and South Tees Miya Emergency expansions; NCIC Smartpage non-clinical and Mizaic EDMSModule expansion strategy working
29 Apr 2026Q3 FY26 4C: operating cash flow A$1.7M; new TCV A$11.7M (~90% recurring); cash A$15.1M; guidance reconfirmed—
18 May 2026Kyra flow products acquisition announced (A$3.0M + up to A$1.0M earn-out); shares up ~6% intradayFirst acquisition since 2021
25 May 2026UH Sussex 7-year EPR contract signed: ≈A$35M minimum TCV, potential A$45M+; ≈A$8.5M FY26 revenueLargest UK EPR contract to date
28–29 May 2026606,060 shares issued in lieu of cash for servicesMinor dilution
29 Jun 2026Kyra completed; FY26 trading update reconfirms guidance—
Q4 FY26Western Health 4+1-year extension with expansion to additional bedsKey Victorian reference site retained
Q4 FY26NCIC Phase 1 Miya Precision EPR go-live, delivered on timeDe-risks EPR delivery credentials
23 Jul 2026Q4 FY26 4C: record operating cash flow A$7.7M; receipts A$24.6M incl. A$10.6M UH Sussex upfront; Q4 TCV A$43.2M; cash A$20.6MCash generation inflection
19 Aug 2026FY26 results: revenue A$51.6M (+27%), Underlying EBITDA A$6.8M (+34%), NPAT A$2.3M (+38%), ARR A$38.3M, FY27 contracted A$44.9M; FY27 revenue and EBITDA to exceed FY26Record year; positive guidance
3 Sep 2026ASX relieves Alcidion from quarterly 4C reportingReflects financial strength; fewer reporting touchpoints for investors
Oct 2026 (expected)2026 AGM–

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue rose from AUD 34.4 Mn in FY2022 to AUD 51.6 Mn in FY2026.
Alcidion Group Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue34.440.437.140.851.6
Cost of revenue4.95.65.14.810.2
Gross profit29.534.831.93641.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.